Glioma Diagnosis and Treatment

This study investigates vortioxetine's anti-cancer effects on glioblastoma cells using cell viability and migration assays, showing suppression of cell growth and survival.

This study identifies proteomic subtypes and recurrence patterns in IDH-wildtype glioblastoma using tissue and serum samples, revealing prognostic markers and proteomic plasticity in recurrent tumors.

This study identifies two DCD-related subtypes in glioma with distinct prognostic and immune characteristics using a risk score model based on DCD genes.

This paper describes methods for generating zebrafish PDX systems to study GSC-mediated tumorigenesis and interactions with the tumor microenvironment.

This study shows that emodin inhibits glioma cell proliferation, invasion, and induces apoptosis by modulating the PI3K-AKT and NF-B pathways.

This study identifies UBE2C as a prognostic biomarker in glioma, linked to immunosuppression and invasiveness through IL6/IL10 and MMP pathways.

This study identifies cell-state plasticity as a driver of heterogeneity in Group 3/4 medulloblastomas, showing that transcription factor perturbation can redirect tumor cells along different differentiation trajectories.

This study identifies that glioblastoma cells in the tumor's invasive leading edge exhibit electrophysiological properties similar to neurons, including action potentials, and show reduced proliferation signaling.

This study analyzes PIH1D1 and p53 expression in pediatric brain tumors using TCGA data, identifying them as potential prognostic markers and therapeutic targets.

This study characterizes the mutational landscape of high-grade gliomas in a Chilean cohort, identifying novel mutations and highlighting genetic differences compared to non-Latin American populations.

This study uses a network dynamics model to analyze glioma stem cells' role in glioma hierarchy, identifying stable states and transitional states linked to tumor heterogeneity and therapy resistance.

The paper investigates RIPK1 expression in Diffuse Gliomas using TCGA data, finding higher RIPK1 expression in wild-type IDH tumors and associating it with poor prognosis and immune infiltration.

This study uses single-nucleus RNA sequencing to analyze a mouse glioblastoma model, identifying potential therapeutic targets and similarities with human GBM subtypes.

This study shows ASCL1 and OLIG2 regulate glioblastoma initiation, migration, and cell types through their dynamic interactions and target gene regulation.

This study identifies the neuronal H+-Asic1a axis as a regulator of neuron-glioma synapses, showing reduced tumor growth in Asic1a-deficient mice.

This study identifies BIRC3 as a prognostic biomarker and therapeutic target for TMZ-resistant glioblastoma, validated across multiple datasets and showing efficacy when combined with AZD5582.

This study shows that DDX3X mutations in medulloblastoma impair translation-promoting activity but retain function in stress granules and interferon signaling, suggesting helicase activity as a tumor suppressor.

The paper develops EGFRvIII-targeting peptides using in silico modeling and phage display to detect and target refractory glioblastoma tumors without affecting wild-type EGFR.

The paper identifies an epigenetic neural signature in glioblastoma that correlates with poor prognosis and therapeutic vulnerability.

This paper develops a Drosophila melanogaster model of DIPG by overexpressing H3K27 and Myc in glial cells, revealing distinct molecular features compared to glioblastoma.

This study identifies the PTEN-NF-κB-BRD2 pathway as critical for glioblastoma mesenchymal transition and invasion, suggesting BET-BD2 inhibitors as a therapeutic strategy.

This study shows that H3.3-G34R mutations reprogram the tumor immune microenvironment in diffuse hemispheric gliomas, enhancing the efficacy of immune stimulatory gene therapy and leading to long-term survival in treated mice.

This paper identifies a matrix code based on extracellular core matrix proteins that categorizes glioblastoma tumors into prognostic groups and predicts responses to PD1 blockade.

This study evaluates gedunin's effects on glioblastoma proliferation and invasiveness using in vitro and in vivo models, finding it reduces cell growth and migration but has limited impact on tumor volume.

This study identifies glioma subtypes using multi-omics data and finds that cluster A has better prognosis and lower proliferation, while cluster B has worse prognosis and higher EMT activation.

This study uses an explainable AI model to classify chronic inflammatory responses as prognostic markers for glioma using TCGA data, identifying five inflammatory profiles linked to survival outcomes.

This study develops human iPSC-derived tumor models to investigate the cooperative effects of H3.3K27M and PDGFRA mutations in DMG, identifying therapeutic vulnerabilities.

The paper combines five RNA-seq datasets to create a reference landscape of human brain tissues and tumors, enabling comparative gene expression analysis across normal and neoplastic samples.

This study identifies FCGRT as a prognostic factor in glioma, showing its role in promoting tumor proliferation and invasion through interaction with CIgG.

This paper introduces a conditional H3.3K27M mutation in mice to model paediatric diffuse intrinsic pontine glioma, showing dwarfism with intact growth hormone signaling.